{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:51:33Z","timestamp":1783075893021,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,11,28]],"date-time":"2015-11-28T00:00:00Z","timestamp":1448668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00228-015-1982-0","type":"journal-article","created":{"date-parts":[[2015,11,27]],"date-time":"2015-11-27T18:49:48Z","timestamp":1448650188000},"page":"285-293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings"],"prefix":"10.1007","volume":"72","author":[{"given":"Marco","family":"Pozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Fucile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Bravaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liberata","family":"Sportiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Bertella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Auricchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ferrajolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Guastella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Carnovale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Rafaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Scuderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Sperandeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pascotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Radice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,28]]},"reference":[{"key":"1982_CR1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40272-013-0024-6","volume":"15","author":"S Caccia","year":"2013","unstructured":"Caccia S (2013) Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Pediatr Drugs 15:217\u2013233","journal-title":"Pediatr Drugs"},{"key":"1982_CR2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/070674370404900503","volume":"49","author":"L Haan de","year":"2004","unstructured":"de Haan L, Lavalaye J, van Bruggen M, et al. (2004) Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatr 49:290\u2013296","journal-title":"Can J Psychiatr"},{"key":"1982_CR3","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/jcbfm.2011.54","volume":"31","author":"E Kim","year":"2011","unstructured":"Kim E, Howes OD, Yu KS, et al. (2011) Calculating occupancy when one does not have baseline: a comparison of different options. J Cereb Blood Flow Metab 31:1760\u20131767","journal-title":"J Cereb Blood Flow Metab"},{"key":"1982_CR4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.phrs.2013.01.002","volume":"70","author":"PN McCormick","year":"2013","unstructured":"McCormick PN, Wilson VS, Wilson AA, Remington GJ (2013) Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors. Pharmacol Res 70:66\u201371","journal-title":"Pharmacol Res"},{"key":"1982_CR5","unstructured":"Pellegrino P, Clementi E, Capuano A, Radice S (2014) Can vaccines interact with drug metabolism? Pharmacol Res pii:S1043-6618(14)00147\u201300149."},{"key":"1982_CR6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/pch\/16.9.581","volume":"16","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Panagiotopoulos C, Davidson J, et al. (2011) Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health 16:581\u2013589","journal-title":"Paediatr Child Health"},{"key":"1982_CR7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","volume":"100","author":"E Spina","year":"2007","unstructured":"Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100:4\u201322","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1982_CR8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","volume":"31","author":"H Uchida","year":"2011","unstructured":"Uchida H, Takeuchi H, Graff-Guerrero A, et al. (2011) Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol 31:497\u2013502","journal-title":"J Clin Psychopharmacol"},{"key":"1982_CR9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/FTD.0000000000000041","volume":"36","author":"L Best-Shaw","year":"2014","unstructured":"Best-Shaw L, Gudbrandsen M, Nagar J, et al. (2014) Psychiatrists\u2019 perspectives on antipsychotic dose and the role of plasma concentration therapeutic drug monitoring. Ther Drug Monit 36:486\u2013493","journal-title":"Ther Drug Monit"},{"key":"1982_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N, et al. (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195\u2013235","journal-title":"Pharmacopsychiatry"},{"key":"1982_CR11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/cap.2014.0044","volume":"25","author":"Z Whitney","year":"2015","unstructured":"Whitney Z, Boyda HN, Procyshyn RM, et al. (2015) Therapeutic drug levels of second generation antipsychotics in youth: a systematic review. J Child Adolesc Psychopharmacol 25:234\u2013245","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1982_CR12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1517\/14740338.2014.928692","volume":"13","author":"C Carnovale","year":"2014","unstructured":"Carnovale C, Brusadelli T, Zuccotti G, et al. (2014) The importance of monitoring adverse drug reactions in pediatric patients: the results of a national surveillance program in Italy. Expert Opin Drug Saf 13:S1\u2013S8","journal-title":"Expert Opin Drug Saf"},{"key":"1982_CR13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1176\/appi.ps.005482012","volume":"64","author":"DM Hartung","year":"2013","unstructured":"Hartung DM, Middleton L, McFarland BH, et al. (2013) Use of administrative data to identify off-label use of second-generation antipsychotics in a Medicaid population. Psychiatr Serv 64:1236\u20131242","journal-title":"Psychiatr Serv"},{"key":"1982_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2012.09.012","volume":"67","author":"M Jin","year":"2013","unstructured":"Jin M, Min C, Zheng M, et al. (2013) Multiple signaling routes involved in the regulation of adenylyl cyclase and extracellular regulated kinase by dopamine D(2) and D(3) receptors. Pharmacol Res 67:31\u201341","journal-title":"Pharmacol Res"},{"key":"1982_CR15","first-page":"e109","volume":"18","author":"DL Leslie","year":"2012","unstructured":"Leslie DL, Rosenheck R (2012) Off-label use of antipsychotic medications in Medicaid. Am J Manag Care 18:e109\u2013e117","journal-title":"Am J Manag Care"},{"key":"1982_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.11.008","volume":"80","author":"A Luoni","year":"2014","unstructured":"Luoni A, Fumagalli F, Racagni G, Riva MA (2014) Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain. Pharmacol Res 80:1\u20138","journal-title":"Pharmacol Res"},{"key":"1982_CR17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11920-013-0426-8","volume":"15","author":"RB Penfold","year":"2013","unstructured":"Penfold RB, Stewart C, Hunkeler EM, et al. (2013) Use of antipsychotic medications in pediatric populations: what do the data say? Curr Psychiatry Rep 15:426","journal-title":"Curr Psychiatry Rep"},{"key":"1982_CR18","unstructured":"Risperdal\u2013Janssen Cilag, Belgium. Official EMA label. Last accessed June 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Risperdal_30\/WC500007979.pdf"},{"key":"1982_CR19","unstructured":"Risperdal\u2013Janssen Cilag, Belgium. Official FDA label. Last accessed June 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020272s073 ,020588s062,021444s048lbl.pdf"},{"key":"1982_CR20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/cap.2010.0038","volume":"21","author":"CA Calarge","year":"2011","unstructured":"Calarge CA, Miller del D (2011) Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol 21:163\u2013169","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1982_CR21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/104454604773840472","volume":"14","author":"A Gagliano","year":"2004","unstructured":"Gagliano A, German\u00f2 E, Pustorino G, et al. (2004) Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14:39\u201347","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1982_CR22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/dmcn.12470","volume":"56","author":"I Youngster","year":"2014","unstructured":"Youngster I, Zachor DA, Gabis LV, et al. (2014) CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Dev Med Child Neurol 56:990\u2013994","journal-title":"Dev Med Child Neurol"},{"key":"1982_CR23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1055\/s-0029-1239540","volume":"43","author":"K Klampfl","year":"2010","unstructured":"Klampfl K, Taurines R, Preuss A, et al. (2010) Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry 43:58\u201365","journal-title":"Pharmacopsychiatry"},{"key":"1982_CR24","unstructured":"Abilify\u2013Otsuka, Japan. Official EMA label. Last accessed June 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000471\/WC500020170.pdf"},{"key":"1982_CR25","unstructured":"Abilify\u2013Otsuka, Japan. Official FDA label. Last accessed June 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021436s036 ,021866s021,021729s020,021713s028lbl.pdf"},{"key":"1982_CR26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pediatrneurol.2012.08.015","volume":"47","author":"R Rizzo","year":"2012","unstructured":"Rizzo R, Eddy CM, Cal\u00ed P, et al. (2012) Metabolic effects of aripiprazole and pimozide in children with Tourette syndrome. Pediatr Neurol 47:419\u2013422","journal-title":"Pediatr Neurol"},{"key":"1982_CR27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1155\/2013\/626410","volume":"26","author":"K Waldon","year":"2013","unstructured":"Waldon K, Hill J, Termine C, et al. (2013) Trials of pharmacological interventions for Tourette syndrome: a systematic review. Behav Neurol 26:265\u2013273","journal-title":"Behav Neurol"},{"key":"1982_CR28","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","volume":"168","author":"TS Stroup","year":"2011","unstructured":"Stroup TS, McEvoy JP, Ring KD, et al. (2011) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168:947\u2013956","journal-title":"Am J Psychiatry"},{"key":"1982_CR29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/cap.2008.0111","volume":"19","author":"RL Findling","year":"2009","unstructured":"Findling RL, Kauffman R, Sallee FR, et al. (2009) An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 19:431\u2013439","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1982_CR30","unstructured":"Zyprexa\u2013Eli Lilly, IN, USA. Official EMA label. Last accessed June 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000115\/WC500055207.pdf"},{"key":"1982_CR31","unstructured":"Zyprexa\u2013Eli Lilly, IN, USA. Official FDA label. Last accessed June 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020592s063 ,021086s041lbl.pdf"},{"key":"1982_CR32","unstructured":"Seroquel\u2013Astra Zeneca, UK. Official EMA label. Last accessed June 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Seroquel_Seroquel__XR_30\/WC500167535.pdf"},{"key":"1982_CR33","unstructured":"Seroquel\u2013Astra Zeneca, UK. Official FDA label. Last accessed June 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020639s061lbl.pdf"},{"key":"1982_CR34","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1185\/030079908X297385","volume":"24","author":"DE Faries","year":"2008","unstructured":"Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ (2008) Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin 24:1399\u20131405","journal-title":"Curr Med Res Opin"},{"key":"1982_CR35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/FTD.0b013e3181633429","volume":"30","author":"CJ Bachmann","year":"2008","unstructured":"Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M, et al. (2008) Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit 30:108\u2013112","journal-title":"Ther Drug Monit"},{"key":"1982_CR36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/01.chi.0000219832.23849.31","volume":"45","author":"RL Findling","year":"2006","unstructured":"Findling RL, Reed MD, O\u2019Riordan MA, et al. (2006) Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry 45:792\u2013800","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1982_CR37","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/rcm.2537","volume":"20","author":"J Bhatt","year":"2006","unstructured":"Bhatt J, Subbaiah G, Singh S (2006) Liquid chromatography\/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma. Rapid Commun Mass Spectrom 20:2109\u20132114","journal-title":"Rapid Commun Mass Spectrom"},{"key":"1982_CR38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/jat\/33.5.237","volume":"33","author":"SN Lin","year":"2009","unstructured":"Lin SN, Lamm L, Newton TF, et al. (2009) A liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitation of aripiprazole in human plasma. J Anal Toxicol 33:237\u2013242","journal-title":"J Anal Toxicol"},{"key":"1982_CR39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jchromb.2003.11.037","volume":"802","author":"Z Zhou","year":"2004","unstructured":"Zhou Z, Li X, Li K, et al. (2004) Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 802:257\u2013262","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1982_CR40","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s002130050726","volume":"139","author":"M Aravagiri","year":"1998","unstructured":"Aravagiri M, Yuwiler A, Marder SR (1998) Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 139:356\u2013363","journal-title":"Psychopharmacology"},{"key":"1982_CR41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007691-200008000-00019","volume":"22","author":"E Spina","year":"2000","unstructured":"Spina E, Avenoso A, Facciol\u00e0 G, et al. (2000) Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 22:481\u2013485","journal-title":"Ther Drug Monit"},{"key":"1982_CR42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-2007-977715","volume":"40","author":"I Castberg","year":"2007","unstructured":"Castberg I, Spigset O (2007) Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry 40:107\u2013110","journal-title":"Pharmacopsychiatry"},{"key":"1982_CR43","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1089\/cap.2012.0094","volume":"23","author":"M Pozzi","year":"2013","unstructured":"Pozzi M, Bertella S, Cattaneo D, et al. (2013) Are non-serious adverse reactions to psychiatric drugs really non-serious? J Child Adolesc Psychopharmacol 23:394\u2013400","journal-title":"J Child Adolesc Psychopharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1982-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1982-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1982-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T21:03:23Z","timestamp":1567371803000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1982-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,28]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["1982"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1982-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,28]]}}}